Conclusions

Overall, data from the SENSCIS trial suggested that the effect of nintedanib on slowing the progression of SSc-ILD observed over 52 weeks persists over at least 100 weeks.
The adverse event profile of nintedanib over 100 weeks was consistent with that reported over 52 weeks and characterized mainly by diarrhea.
These findings suggest that nintedanib provides a clinically meaningful benefit on slowing the progression of SSc-ILD, with side-effects that are manageable for most patients.